Skip to main content
NCBI home page
Gut logoLink to Gut
. 1995 Oct;37(4):449–454. doi: 10.1136/gut.37.4.449

The management of chronic hepatitis C virus infection.

J C Booth 1, J L Brown 1, H C Thomas 1
PMCID: PMC1382891  PMID: 7489926

Full text

PDF
449

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akahane Y., Kojima M., Sugai Y., Sakamoto M., Miyazaki Y., Tanaka T., Tsuda F., Mishiro S., Okamoto H., Miyakawa Y. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med. 1994 May 1;120(9):748–752. doi: 10.7326/0003-4819-120-9-199405010-00005. [DOI] [PubMed] [Google Scholar]
  2. Alberti A., Morsica G., Chemello L., Cavalletto D., Noventa F., Pontisso P., Ruol A. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet. 1992 Sep 19;340(8821):697–698. doi: 10.1016/0140-6736(92)92234-7. [DOI] [PubMed] [Google Scholar]
  3. Alter M. J., Margolis H. S., Krawczynski K., Judson F. N., Mares A., Alexander W. J., Hu P. Y., Miller J. K., Gerber M. A., Sampliner R. E. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992 Dec 31;327(27):1899–1905. doi: 10.1056/NEJM199212313272702. [DOI] [PubMed] [Google Scholar]
  4. Bellentani S., Podda M., Tiribelli C., Callea F., Marazzi M., Sodde M., Merlini R., Batezzati P. M., Crosignani A., Zuin M. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J Hepatol. 1993 Nov;19(3):459–464. doi: 10.1016/s0168-8278(05)80558-6. [DOI] [PubMed] [Google Scholar]
  5. Bjøro K., Frøland S. S., Yun Z., Samdal H. H., Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994 Dec 15;331(24):1607–1611. doi: 10.1056/NEJM199412153312402. [DOI] [PubMed] [Google Scholar]
  6. Booth J. C., Foster G. R., Kumar U., Galassini R., Goldin R. D., Brown J. L., Thomas H. C. Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha. Gut. 1995 Mar;36(3):427–432. doi: 10.1136/gut.36.3.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Botarelli P., Brunetto M. R., Minutello M. A., Calvo P., Unutmaz D., Weiner A. J., Choo Q. L., Shuster J. R., Kuo G., Bonino F. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology. 1993 Feb;104(2):580–587. doi: 10.1016/0016-5085(93)90430-k. [DOI] [PubMed] [Google Scholar]
  8. Boucher E., Jouanolle H., Andre P., Ruffault A., Guyader D., Moirand R., Turlin B., Jacquelinet C., Brissot P., Deugnier Y. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepatology. 1995 Feb;21(2):322–327. [PubMed] [Google Scholar]
  9. Bresters D., Mauser-Bunschoten E. P., Reesink H. W., Roosendaal G., van der Poel C. L., Chamuleau R. A., Jansen P. L., Weegink C. J., Cuypers H. T., Lelie P. N. Sexual transmission of hepatitis C virus. Lancet. 1993 Jul 24;342(8865):210–211. doi: 10.1016/0140-6736(93)92300-i. [DOI] [PubMed] [Google Scholar]
  10. Bukh J., Purcell R. H., Miller R. H. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):8234–8238. doi: 10.1073/pnas.90.17.8234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Camps J., Castilla A., Ruiz J., Civeira M. P., Prieto J. Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol. 1993 Mar;17(3):390–396. doi: 10.1016/s0168-8278(05)80223-5. [DOI] [PubMed] [Google Scholar]
  12. Caraceni P., Fagiuoli S., Van Thiel D. H. Iron reduction therapy: simply camouflage, or a real weapon? Am J Gastroenterol. 1994 Jul;89(7):970–973. [PubMed] [Google Scholar]
  13. Carreño V., Tapia L., Ryff J. C., Quiroga J. A., Castillo I. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha. J Med Virol. 1992 Jul;37(3):215–219. doi: 10.1002/jmv.1890370312. [DOI] [PubMed] [Google Scholar]
  14. Causse X., Godinot H., Chevallier M., Chossegros P., Zoulim F., Ouzan D., Heyraud J. P., Fontanges T., Albrecht J., Meschievitz C. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991 Aug;101(2):497–502. doi: 10.1016/0016-5085(91)90030-o. [DOI] [PubMed] [Google Scholar]
  15. Chayama K., Kobayashi M., Tsubota A., Koida I., Arase Y., Saitoh S., Ikeda K., Kumada H. Molecular analysis of intraspousal transmission of hepatitis C virus. J Hepatol. 1995 Apr;22(4):431–439. doi: 10.1016/0168-8278(95)80106-5. [DOI] [PubMed] [Google Scholar]
  16. Chemello L., Cavalletto L., Noventa F., Bonetti P., Casarin C., Bernardinello E., Pontisso P., Donada C., Casarin P., Belussi F. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepat. 1995;2(2):91–96. doi: 10.1111/j.1365-2893.1995.tb00012.x. [DOI] [PubMed] [Google Scholar]
  17. Choo Q. L., Kuo G., Ralston R., Weiner A., Chien D., Van Nest G., Han J., Berger K., Thudium K., Kuo C. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1294–1298. doi: 10.1073/pnas.91.4.1294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Choo Q. L., Kuo G., Weiner A. J., Overby L. R., Bradley D. W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989 Apr 21;244(4902):359–362. doi: 10.1126/science.2523562. [DOI] [PubMed] [Google Scholar]
  19. Claeys H., Volkaerts A., Verhaert H., De Beenhouwer H., Vermylen C. Evaluation of anti-HCV capsid indeterminate serum samples. Lancet. 1992 Jul 25;340(8813):249–249. doi: 10.1016/0140-6736(92)90522-5. [DOI] [PubMed] [Google Scholar]
  20. Courouce A. M., Bouchardeau F., Girault A., Le Marrec N. Significance of NS3 and NS5 antigens in screening for HCV antibody. Lancet. 1994 Apr 2;343(8901):853–854. [PubMed] [Google Scholar]
  21. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  22. Delaporte E., Thiers V., Dazza M. C., Romeo R., Mlika-Cabanne N., Aptel I., Schrijvers D., Bréchot C., Larouzé B. High level of hepatitis C endemicity in Gabon, equatorial Africa. Trans R Soc Trop Med Hyg. 1993 Nov-Dec;87(6):636–637. doi: 10.1016/0035-9203(93)90269-v. [DOI] [PubMed] [Google Scholar]
  23. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Goodman Z., Banks S. M., Hoofnagle J. H. A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis. J Hepatol. 1990;11 (Suppl 1):S36–S42. doi: 10.1016/0168-8278(90)90161-j. [DOI] [PubMed] [Google Scholar]
  24. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  25. Di Bisceglie A. M., Shindo M., Fong T. L., Fried M. W., Swain M. G., Bergasa N. V., Axiotis C. A., Waggoner J. G., Park Y., Hoofnagle J. H. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992 Sep;16(3):649–654. doi: 10.1002/hep.1840160307. [DOI] [PubMed] [Google Scholar]
  26. Dienes H. P., Popper H., Arnold W., Lobeck H. Histologic observations in human hepatitis non-A, non-B. Hepatology. 1982 Sep-Oct;2(5):562–571. doi: 10.1002/hep.1840020509. [DOI] [PubMed] [Google Scholar]
  27. Dusheiko G., Schmilovitz-Weiss H., Brown D., McOmish F., Yap P. L., Sherlock S., McIntyre N., Simmonds P. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology. 1994 Jan;19(1):13–18. [PubMed] [Google Scholar]
  28. Esteban J. I., Esteban R., Viladomiu L., López-Talavera J. C., González A., Hernández J. M., Roget M., Vargas V., Genescà J., Buti M. Hepatitis C virus antibodies among risk groups in Spain. Lancet. 1989 Aug 5;2(8658):294–297. doi: 10.1016/s0140-6736(89)90485-6. [DOI] [PubMed] [Google Scholar]
  29. Fagan E. A., Harrison T. J. Exclusion in liver by polymerase chain reaction of hepatitis B and C viruses in acute liver failure attributed to sporadic non-A, non-B hepatitis. J Hepatol. 1994 Oct;21(4):587–591. doi: 10.1016/s0168-8278(94)80106-1. [DOI] [PubMed] [Google Scholar]
  30. Farinati F., Cardin R., De Maria N., Della Libera G., Marafin C., Lecis E., Burra P., Floreani A., Cecchetto A., Naccarato R. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol. 1995 Apr;22(4):449–456. doi: 10.1016/0168-8278(95)80108-1. [DOI] [PubMed] [Google Scholar]
  31. Ferenci P., Vogel W., Pristautz H., Deimer J., Denk H., Judmaier G., Maier K. P., Krejs G. J., Gangl A. One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b. J Hepatol. 1990;11 (Suppl 1):S50–S53. doi: 10.1016/0168-8278(90)90163-l. [DOI] [PubMed] [Google Scholar]
  32. Gabrielli C., Zannini A., Corradini R., Gafa S. Spread of hepatitis C virus among sexual partners of HCVAb positive intravenous drug users. J Infect. 1994 Jul;29(1):17–22. doi: 10.1016/s0163-4453(94)94952-2. [DOI] [PubMed] [Google Scholar]
  33. Gilmore I. T., Burroughs A., Murray-Lyon I. M., Williams R., Jenkins D., Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 1995 Mar;36(3):437–441. doi: 10.1136/gut.36.3.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Giovannini M., Tagger A., Ribero M. L., Zuccotti G., Pogliani L., Grossi A., Ferroni P., Fiocchi A. Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet. 1990 May 12;335(8698):1166–1166. doi: 10.1016/0140-6736(90)91174-9. [DOI] [PubMed] [Google Scholar]
  35. Gordon S. C., Elloway R. S., Long J. C., Dmuchowski C. F. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology. 1993 Dec;18(6):1338–1343. [PubMed] [Google Scholar]
  36. Gómez-Rubio M., Porres J. C., Castillo I., Quiroga J. A., Moreno A., Carreño V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol. 1990;11 (Suppl 1):S63–S67. doi: 10.1016/0168-8278(90)90166-o. [DOI] [PubMed] [Google Scholar]
  37. Hagiwara H., Hayashi N., Mita E., Takehara T., Kasahara A., Fusamoto H., Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 1993 Mar;104(3):877–883. doi: 10.1016/0016-5085(93)91025-d. [DOI] [PubMed] [Google Scholar]
  38. Hayashi H., Takikawa T., Nishimura N., Yano M., Isomura T., Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol. 1994 Jul;89(7):986–988. [PubMed] [Google Scholar]
  39. Hoffmann R. M., Diepolder H. M., Zachoval R., Zwiebel F. M., Jung M. C., Scholz S., Nitschko H., Riethmüller G., Pape G. R. Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology. 1995 Mar;21(3):632–638. [PubMed] [Google Scholar]
  40. Honda M., Kaneko S., Sakai A., Unoura M., Murakami S., Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology. 1994 Nov;20(5):1144–1151. [PubMed] [Google Scholar]
  41. Hoofnagle J. H., Mullen K. D., Jones D. B., Rustgi V., Di Bisceglie A., Peters M., Waggoner J. G., Park Y., Jones E. A. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986 Dec 18;315(25):1575–1578. doi: 10.1056/NEJM198612183152503. [DOI] [PubMed] [Google Scholar]
  42. Hopf U., Möller B., Küther D., Stemerowicz R., Lobeck H., Lüdtke-Handjery A., Walter E., Blum H. E., Roggendorf M., Deinhardt F. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol. 1990 Jan;10(1):69–76. doi: 10.1016/0168-8278(90)90075-3. [DOI] [PubMed] [Google Scholar]
  43. Iino S., Hino K., Kuroki T., Suzuki H., Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci. 1993 Apr;38(4):612–618. doi: 10.1007/BF01316789. [DOI] [PubMed] [Google Scholar]
  44. Irving W. L., Day S., Eglin R. P., Bennett D. P., Neal K. R., Jones D. A., James V. Hepatitis C in blood donors. Lancet. 1993 Mar 27;341(8848):835–836. doi: 10.1016/0140-6736(93)90617-p. [DOI] [PubMed] [Google Scholar]
  45. Jacyna M. R., Brooks M. G., Loke R. H., Main J., Murray-Lyon I. M., Thomas H. C. Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. BMJ. 1989 Jan 14;298(6666):80–82. doi: 10.1136/bmj.298.6666.80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Jouët P., Roudot-Thoraval F., Dhumeaux D., Métreau J. M. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C. Gastroenterology. 1994 Mar;106(3):686–690. doi: 10.1016/0016-5085(94)90703-x. [DOI] [PubMed] [Google Scholar]
  47. Kaito M., Watanabe S., Tsukiyama-Kohara K., Yamaguchi K., Kobayashi Y., Konishi M., Yokoi M., Ishida S., Suzuki S., Kohara M. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol. 1994 Jul;75(Pt 7):1755–1760. doi: 10.1099/0022-1317-75-7-1755. [DOI] [PubMed] [Google Scholar]
  48. Kanai K., Kako M., Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet. 1992 Jun 20;339(8808):1543–1543. doi: 10.1016/0140-6736(92)91311-u. [DOI] [PubMed] [Google Scholar]
  49. Kao J. H., Chen P. J., Lei M. Y., Wang T. H., Chen D. S. Sexual transmission of HCV. Lancet. 1993 Sep 4;342(8871):626–626. [PubMed] [Google Scholar]
  50. Kao J. H., Chen P. J., Yang P. M., Lai M. Y., Sheu J. C., Wang T. H., Chen D. S. Intrafamilial transmission of hepatitis C virus: the important role of infections between spouses. J Infect Dis. 1992 Oct;166(4):900–903. doi: 10.1093/infdis/166.4.900. [DOI] [PubMed] [Google Scholar]
  51. Kasahara A., Hayashi N., Hiramatsu N., Oshita M., Hagiwara H., Katayama K., Kato M., Masuzawa M., Yoshihara H., Kishida Y. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology. 1995 Feb;21(2):291–297. [PubMed] [Google Scholar]
  52. Kumar U., Brown J., Monjardino J., Thomas H. C. Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis. 1993 Mar;167(3):726–730. doi: 10.1093/infdis/167.3.726. [DOI] [PubMed] [Google Scholar]
  53. Kumar U., Thomas H. C., Monjardino J. Serum HCV RNA levels in chronic HCV hepatitis measured by quantitative PCR assay; correlation with serum AST. J Virol Methods. 1994 Apr;47(1-2):95–102. doi: 10.1016/0166-0934(94)90069-8. [DOI] [PubMed] [Google Scholar]
  54. Kuo G., Choo Q. L., Alter H. J., Gitnick G. L., Redeker A. G., Purcell R. H., Miyamura T., Dienstag J. L., Alter M. J., Stevens C. E. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989 Apr 21;244(4902):362–364. doi: 10.1126/science.2496467. [DOI] [PubMed] [Google Scholar]
  55. Lau J. Y., Davis G. L., Kniffen J., Qian K. P., Urdea M. S., Chan C. S., Mizokami M., Neuwald P. D., Wilber J. C. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 1993 Jun 12;341(8859):1501–1504. doi: 10.1016/0140-6736(93)90635-t. [DOI] [PubMed] [Google Scholar]
  56. Lefkowitch J. H., Schiff E. R., Davis G. L., Perrillo R. P., Lindsay K., Bodenheimer H. C., Jr, Balart L. A., Ortego T. J., Payne J., Dienstag J. L. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology. 1993 Feb;104(2):595–603. doi: 10.1016/0016-5085(93)90432-c. [DOI] [PubMed] [Google Scholar]
  57. Makris M., Preston F. E., Triger D. R., Underwood J. C., Westlake L., Adelman M. I. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood. 1991 Oct 1;78(7):1672–1677. [PubMed] [Google Scholar]
  58. Manzini P., Saracco G., Cerchier A., Riva C., Musso A., Ricotti E., Palomba E., Scolfaro C., Verme G., Bonino F. Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern. Hepatology. 1995 Feb;21(2):328–332. [PubMed] [Google Scholar]
  59. Martin P., Di Bisceglie A. M., Kassianides C., Lisker-Melman M., Hoofnagle J. H. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology. 1989 Dec;97(6):1559–1561. doi: 10.1016/0016-5085(89)90405-8. [DOI] [PubMed] [Google Scholar]
  60. Martinot-Peignoux M., Marcellin P., Gournay J., Gabriel F., Courtois F., Branger M., Wild A. M., Erlinger S., Benhamou J. P. Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol. 1994 May;20(5):676–678. doi: 10.1016/s0168-8278(05)80360-5. [DOI] [PubMed] [Google Scholar]
  61. McOmish F., Chan S. W., Dow B. C., Gillon J., Frame W. D., Crawford R. J., Yap P. L., Follett E. A., Simmonds P. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion. 1993 Jan;33(1):7–13. doi: 10.1046/j.1537-2995.1993.33193142314.x. [DOI] [PubMed] [Google Scholar]
  62. Mutimer D. J., Harrison R. F., O'Donnell K. B., Shaw J., Martin B. A., Atrah H., Ala F. A., Skidmore S., Hubscher S. G., Neuberger J. M. Hepatitis C virus infection in the asymptomatic British blood donor. J Viral Hepat. 1995;2(1):47–53. doi: 10.1111/j.1365-2893.1995.tb00071.x. [DOI] [PubMed] [Google Scholar]
  63. Nalpas B., Thiers V., Pol S., Driss F., Thepot V., Berthelot P., Brechot C. Hepatitis C viremia and anti-HCV antibodies in alcoholics. J Hepatol. 1992 Mar;14(2-3):381–384. doi: 10.1016/0168-8278(92)90187-t. [DOI] [PubMed] [Google Scholar]
  64. Ogasawara S., Kage M., Kosai K., Shimamatsu K., Kojiro M. Hepatitis C virus RNA in saliva and breastmilk of hepatitis C carrier mothers. Lancet. 1993 Feb 27;341(8844):561–561. doi: 10.1016/0140-6736(93)90324-a. [DOI] [PubMed] [Google Scholar]
  65. Ogata N., Alter H. J., Miller R. H., Purcell R. H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3392–3396. doi: 10.1073/pnas.88.8.3392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Ohto H., Terazawa S., Sasaki N., Sasaki N., Hino K., Ishiwata C., Kako M., Ujiie N., Endo C., Matsui A. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med. 1994 Mar 17;330(11):744–750. doi: 10.1056/NEJM199403173301103. [DOI] [PubMed] [Google Scholar]
  67. Okamoto H., Sugiyama Y., Okada S., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol. 1992 Mar;73(Pt 3):673–679. doi: 10.1099/0022-1317-73-3-673. [DOI] [PubMed] [Google Scholar]
  68. Olynyk J. K., Reddy K. R., Di Bisceglie A. M., Jeffers L. J., Parker T. I., Radick J. L., Schiff E. R., Bacon B. R. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology. 1995 Apr;108(4):1104–1109. doi: 10.1016/0016-5085(95)90209-0. [DOI] [PubMed] [Google Scholar]
  69. Pawlotsky J. M., Roudot-Thoraval F., Duvoux C., Dhumeaux D., Babany G., Duval J. Virological and biochemical responses to interferon-alpha in chronic hepatitis C. Lancet. 1994 Jan 1;343(8888):54–54. [PubMed] [Google Scholar]
  70. Pereira B. J., Milford E. L., Kirkman R. L., Levey A. S. Transmission of hepatitis C virus by organ transplantation. N Engl J Med. 1991 Aug 15;325(7):454–460. doi: 10.1056/NEJM199108153250702. [DOI] [PubMed] [Google Scholar]
  71. Pozzato G., Moretti M., Franzin F., Crocè L. S., Tiribelli C., Masayu T., Kaneko S., Unoura M., Kobayashi K. Severity of liver disease with different hepatitis C viral clones. Lancet. 1991 Aug 24;338(8765):509–509. doi: 10.1016/0140-6736(91)90578-d. [DOI] [PubMed] [Google Scholar]
  72. Reichard O., Andersson J., Schvarcz R., Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 1991 May 4;337(8749):1058–1061. doi: 10.1016/0140-6736(91)91707-2. [DOI] [PubMed] [Google Scholar]
  73. Rice P. S., Smith D. B., Simmonds P., Holmes E. Heterosexual transmission of hepatitis C virus. Lancet. 1993 Oct 23;342(8878):1052–1053. doi: 10.1016/0140-6736(93)92908-c. [DOI] [PubMed] [Google Scholar]
  74. Ryff J. C. Usefulness of interferon for treatment of hepatitis C. J Hepatol. 1995;22(1 Suppl):101–109. [PubMed] [Google Scholar]
  75. Saeed A. A., al-Admawi A. M., al-Rasheed A., Fairclough D., Bacchus R., Ring C., Garson J. Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh. Lancet. 1991 Aug 17;338(8764):459–460. doi: 10.1016/0140-6736(91)91094-b. [DOI] [PubMed] [Google Scholar]
  76. Sakamoto N., Enomoto N., Kurosaki M., Marumo F., Sato C. Sequential change of the hypervariable region of the hepatitis C virus genome in acute infection. J Med Virol. 1994 Jan;42(1):103–108. doi: 10.1002/jmv.1890420119. [DOI] [PubMed] [Google Scholar]
  77. Saracco G., Rosina F., Abate M. L., Chiandussi L., Gallo V., Cerutti E., Di Napoli A., Solinas A., Deplano A., Tocco A. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology. 1993 Dec;18(6):1300–1305. [PubMed] [Google Scholar]
  78. Scheuer P. J., Ashrafzadeh P., Sherlock S., Brown D., Dusheiko G. M. The pathology of hepatitis C. Hepatology. 1992 Apr;15(4):567–571. doi: 10.1002/hep.1840150402. [DOI] [PubMed] [Google Scholar]
  79. Seeff L. B., Buskell-Bales Z., Wright E. C., Durako S. J., Alter H. J., Iber F. L., Hollinger F. B., Gitnick G., Knodell R. G., Perrillo R. P. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med. 1992 Dec 31;327(27):1906–1911. doi: 10.1056/NEJM199212313272703. [DOI] [PubMed] [Google Scholar]
  80. Simmonds P., Rose K. A., Graham S., Chan S. W., McOmish F., Dow B. C., Follett E. A., Yap P. L., Marsden H. Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. J Clin Microbiol. 1993 Jun;31(6):1493–1503. doi: 10.1128/jcm.31.6.1493-1503.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Simmonds P., Smith D. B., McOmish F., Yap P. L., Kolberg J., Urdea M. S., Holmes E. C. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol. 1994 May;75(Pt 5):1053–1061. doi: 10.1099/0022-1317-75-5-1053. [DOI] [PubMed] [Google Scholar]
  82. Stuyver L., Rossau R., Wyseur A., Duhamel M., Vanderborght B., Van Heuverswyn H., Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 1993 Jun;74(Pt 6):1093–1102. doi: 10.1099/0022-1317-74-6-1093. [DOI] [PubMed] [Google Scholar]
  83. Takase S., Tsutsumi M., Kawahara H., Takada N., Takada A. The alcohol-altered liver membrane antibody and hepatitis C virus infection in the progression of alcoholic liver disease. Hepatology. 1993 Jan;17(1):9–13. [PubMed] [Google Scholar]
  84. Tobler L. H., Busch M. P., Wilber J., Dinello R., Quan S., Polito A., Kochesky R., Bahl C., Nelles M., Lee S. R. Evaluation of indeterminate c22-3 reactivity in volunteer blood donors. Transfusion. 1994 Feb;34(2):130–134. doi: 10.1046/j.1537-2995.1994.34294143940.x. [DOI] [PubMed] [Google Scholar]
  85. Tremolada F., Casarin C., Alberti A., Drago C., Tagger A., Ribero M. L., Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 1992 Nov;16(3):273–281. doi: 10.1016/s0168-8278(05)80657-9. [DOI] [PubMed] [Google Scholar]
  86. Tsubota A., Chayama K., Ikeda K., Yasuji A., Koida I., Saitoh S., Hashimoto M., Iwasaki S., Kobayashi M., Hiromitsu K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 1994 May;19(5):1088–1094. [PubMed] [Google Scholar]
  87. Van Thiel D. H., Friedlander L., Fagiuoli S., Wright H. I., Irish W., Gavaler J. S. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 1994 Mar;20(3):410–415. doi: 10.1016/s0168-8278(94)80017-0. [DOI] [PubMed] [Google Scholar]
  88. Weltman M. D., Brotodihardjo A., Crewe E. B., Farrell G. C., Bilous M., Grierson J. M., Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat. 1995;2(1):39–45. doi: 10.1111/j.1365-2893.1995.tb00070.x. [DOI] [PubMed] [Google Scholar]
  89. Wright T. L., Hsu H., Donegan E., Feinstone S., Greenberg H., Read A., Ascher N. L., Roberts J. P., Lake J. R. Hepatitis C virus not found in fulminant non-A, non-B hepatitis. Ann Intern Med. 1991 Jul 15;115(2):111–112. doi: 10.7326/0003-4819-115-2-111. [DOI] [PubMed] [Google Scholar]
  90. Yamaguchi K., Tanaka E., Higashi K., Kiyosawa K., Matsumoto A., Furuta S., Hasegawa A., Tanaka S., Kohara M. Adaptation of hepatitis C virus for persistent infection in patients with acute hepatitis. Gastroenterology. 1994 May;106(5):1344–1348. doi: 10.1016/0016-5085(94)90029-9. [DOI] [PubMed] [Google Scholar]
  91. Yuki N., Hayashi N., Kamada T. HCV viraemia and liver injury in symptom-free blood donors. Lancet. 1993 Aug 14;342(8868):444–444. doi: 10.1016/0140-6736(93)92863-o. [DOI] [PubMed] [Google Scholar]
  92. Zaaijer H. L., Cuypers H. T., Reesink H. W., Winkel I. N., Gerken G., Lelie P. N. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet. 1993 Mar 20;341(8847):722–724. doi: 10.1016/0140-6736(93)90488-3. [DOI] [PubMed] [Google Scholar]
  93. Zanetti A. R., Tanzi E., Paccagnini S., Principi N., Pizzocolo G., Caccamo M. L., D'Amico E., Cambiè G., Vecchi L. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet. 1995 Feb 4;345(8945):289–291. doi: 10.1016/s0140-6736(95)90277-5. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES